Clinical Trials Browser

Phase 2 × Melanoma × ON 01910 × Clear all

NCT05764395 2026-04-27

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Active not recruiting

Melanoma